STRATEGIES TO ASSESS AND/OR PRODUCE CELL POPULATIONS WITH PREDICTIVE ENGRAFTMENT POTENTIAL

1 .- 238 . (canceled)

239 . A method of sorting a stem cell population comprising

obtaining a biological sample comprising stem cells;

enriching the biological sample for CD34+ cells to create a CD34+ enriched sample; and

isolating CD45RA− and CD90+ cells from the CD34+ enriched sample thereby sorting the stem cell population to create a CD34+/CD45RA−/CD90+ stem cell population.

240 . The method of claim 239 , further comprising isolating CD133+ cells from the CD34+ enriched sample thereby sorting the stem cell population to create a CD34+/CD45RA−/CD90+/CD133+ stem cell population.

241 . The method of claim 239 , further comprising isolating CD117+ cells from the CD34+ enriched sample thereby sorting the stem cell population to create a CD34+/CD45RA−/CD90+/CD117+ stem cell population.

242 . The method of claim 239 , wherein the isolating does not utilize markers other than CD34, CD45RA, and CD90 to sort the stem cell population.

243 . The method of claim 240 , wherein the isolating does not utilize markers other than CD34, CD45RA, CD90, and CD133 to sort the stem cell population.

244 . The method of claim 241 , wherein the isolating does not utilize markers other than CD34, CD45RA, CD90, and CD117 to sort the stem cell population.

245 . The method of claim 239 , wherein the sorting does not utilize CD38 or CD49f to sort the stem cell population.

246 . The method of claim 239 , wherein the isolating does not utilize CD3, CD7, CD10, CD13, CD14, CD33, CD38, CD41, CD56, CD105, CD127, CD135, and CD138 to sort the stem cell population.

247 . The method of claim 239 , wherein the biological sample comprising stem cells comprises umbilical cord blood, placental blood, bone marrow, or peripheral blood.

248 . The method of claim 239 , wherein the enriching comprises positive selection for CD34+ cells using magnetic-assisted cell sorting (MACS) with an anti-CD34 antibody.

249 . The method of claim 239 , wherein the isolating comprises positive selection for CD90+ cells using magnetic-assisted cell sorting (MACS) with an anti-CD90 antibody.

250 . The method of claim 239 , wherein the isolating comprises fluorophore-based nanosorting.

251 . The method of claim 239 , further comprising removing red blood cells from the biological sample.

252 . The method of claim 239 , further comprising genetically-modifying stem cells within the sorted CD34+/CD45RA−/CD90+ stem cell population.

253 . The method of claim 239 , further comprising formulating stem cells within the sorted CD34+/CD45RA−/CD90+ stem cell population for administration to a subject, wherein the cells are formulated at a dose of at least 122,000 cells/kg of the subject.

254 . The method of claim 253 , further comprising formulating a CD34+/CD90− stem cell population for administration to the subject, wherein the CD34+/CD90− stem cell population is not genetically modified.

255 . A method of formulating a cell-based composition for administration to a subject comprising

obtaining a stem cell population sorted according to the method of claim 239 ,

obtaining the weight of the subject,

formulating the stem cell population into a pharmaceutically acceptable carrier at a dose of at least 122,000 cells/kg of the subject.

256 . A stem cell population sorted according to the method of claim 239 , wherein the stem cell population is genetically modified and has a predictive engraftment potential with an R2 score having an absolute value of 0.5 or more, 0.6 or more, 0.7 or more, 0.8 or more, or 0.9 or more.

257 . The stem cell population of claim 255 , wherein the genetic modification comprises a viral vector.

258 . The stem cell population of claim 255 , wherein the genetic modification inserts or alters a gene selected from ABCD1, ABCA3, ABLI, ADA, AKT1, APC, APP, ARSA, ARSB, BCL11A, BLC1, BLC6, BRCA1, BRCA2, BRIP1, C9ORF72, C46, CAR, CAS9, C-CAM, CBFAI, CBL, CCR5, CD4, CD19, CD40, CDA, CFTR, CLN3, C-MYC, CRE, CSCR4, CSFIR, CTLA, CTS-I, CYB5R3, DCC, DHFR, DKC1, DLL1, DMD, EGFR, ERBA, ERBB, EBRB2, ETSI, ETS2, ETV6, F8, F9, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FasL, FCC, FGR, FOX, FUS, FUSI, FYN, GALNS, GATA1, GLB1, GNS, GUSB, HBB, HBD, HBE1, HBG1, HBG2, HCR, HGSNAT, HOXB4, HRAS, HYAL1, ICAM-1, iCaspase, IDUA, IDS, JUN, KLF4, KRAS, LCK, LRRK2, LYN, MCC, MDM2, MGMT, MLL, MMACI, MYB, MEN-I, MEN-II, MYC, NAGLU, NANOG, NF-1, NF-2, NKX2.1, NOTCH, OCT4, p16, p2I, p27, p53, p57, p73, PALB2, PARK2, PARK7, phox, PINK1, PK, PSEN1, PSEN2, PTPN22, RAD51C, ras, RPL3 through RPL40, RPLP0, RPLP1, RPLP2, RPS2-RPS30, RPSA, SFTPB, SFTPC, SGSH, SLX4, SNCA, SOD1, SOX2, TERC, TERT, TDP43, TINF2, TK, ubiquilin 2, VHL, WAS, or WT-I. 1 .- 238 . (canceled)